Abstract 345P
Background
Breast cancer surgery can impair shoulder function, and the effects of rehabilitation exercise during early recovery remain uncertain. This study aims to assess the effectiveness of tailored exercise intervention on shoulder function recovery at one and six months post-surgery.
Methods
A total of 122 breast cancer patients (Stage 0-3) scheduled for surgery were evaluated, and 58 patients (mean age 50.2±6.6 years) were randomly assigned to an exercise or usual care group (1:1). The exercise group underwent five tailored exercise education sessions, starting one day before hospital discharge and continuing for four weeks after surgery. Participants received exercise diaries, online links, and QR codes for home-based workouts. The primary outcome measured the proportion of participants achieving 90% of their pre-surgery shoulder ROM and strength at one and six months post-surgery. Secondary measures included DASH and SPADI scores, physical activity levels, and body composition.
Results
Out of 58 participants, 56 (96.6%) completed the trial, with a 96.6% exercise compliance rate one month after surgery. In the exercise group, 92.9% and 96.2% achieved pre-surgery shoulder strength levels at one and six months post-surgery, respectively, compared to 3.7% and 32.1% in the control group. The exercise group also exhibited significantly lower shoulder pain and disability scores (SPADI) at one and six months after surgery, as well as higher physical activity levels at six months. Table: 345P
Change in shoulder strength among postoperative breast cancer patients
Affected arm | |||
EPET (n=25) | Usual Care (n=26) | p | |
Sum of strength (Ib) | |||
T0 | 44.1±10.2 | 47.5±11.1 | 0.36 |
T1 | 23.2±10.3∗∗∗ | 23.8±9.4∗∗∗ | 0.80 |
T2 | 40.4±11.9 | 28.5±11.9∗∗∗ | 0.001 |
T3 | 45.9±14.7 | 32.0±11.2∗∗∗ | <0.001 |
T4 | 51.3±14.0 | 32.0±9.2∗∗∗ | <0.001 |
T5 | 61.0±17.1∗∗∗ | 38.3±8.4∗∗∗ | <0.001 |
Mean±SD, P=represented the results of independent T-test (the p-value adjusted for Bonferroni method (0.05/6=0.0083), *=represented paired t-test [**p<0.01 vs. baseline, ***p<0.001 vs. baseline (p-value adjusted for Bonferroni method)] Abbreviation: early postoperative exercise therapy; EPET
.Conclusions
Early implementation of tailored exercise during rehabilitation significantly improved shoulder function beyond pre-surgery levels. This study provides essential insights into the efficacy and safety of early rehabilitation exercises for breast cancer patients during the post-surgery recovery phase.
Clinical trial identification
The Institutional Ethics Review Board of Severance Hospital and WHO International Clinical Trials Registry Platform (ICTRP; KCT0006997) approved the trial.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research was supported by the Ministry of Education of the Republic of Korea, the National Research Foundation of Korea (NRF-2020S1A5B5A17090332) and Korea Breast Cancer Foundation (KBCF-2020U002).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
371P - Adherence to standardized and structured electronic symptom reporting (ePRO) via mobile app in HER2-positive breast cancer treated with HER2 biosimilar trastuzumab
Presenter: Andreas Trojan
Session: Poster session 03
372P - Prevalence of BRCA1 and BRCA2 mutation among Indian breast cancer patients: A multicentre cross-sectional study
Presenter: Shona Nag
Session: Poster session 03
374P - Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial
Presenter: Amrita Basu
Session: Poster session 03
375TiP - A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors
Presenter: Ludimila Cavalcante
Session: Poster session 03
388P - Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC)
Presenter: Junji Tsurutani
Session: Poster session 03
391P - Detrimental effect on overall survival of CDK4/6 inhibitor dose reduction if immortal time bias is considered
Presenter: Andreas Bjerrum
Session: Poster session 03
392P - The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer on first-line endocrine therapy with or without a CDK 4/6 inhibitor
Presenter: Senna Lammers
Session: Poster session 03